plus 2, Susan G. Komen for the Cure(R) Honored as Most Valued Non-Profit Brand ... - Stockhouse |
- Susan G. Komen for the Cure(R) Honored as Most Valued Non-Profit Brand ... - Stockhouse
- Most Early-Stage Breast Cancer Patients May Not Need Radiation After Mastectomy - Science Daily
- Corning Inc. and Susan G. Komen group join to increase cancer awareness - Star-Gazette
| Susan G. Komen for the Cure(R) Honored as Most Valued Non-Profit Brand ... - Stockhouse Posted: 08 Mar 2010 09:58 AM PST Despite Tremendous Honor, Progress, Work is "Far from Done," Founder and CEO Says DALLAS, Mar 08, 2010 (BUSINESS WIRE) -- Top rankings for brand value, trust, and the charity people are most likely to donate to, affirm the strength of the 28-year promise of Susan G. Komen for the Cure(R): the world's largest breast cancer organization: to save lives and end breast cancer forever. The 2010 rankings of non-profit organizations from global market research firm Harris Interactive last week ranked Komen for the Cure as the number one most valuable non-profit brand and the charity people are most likely to donate to. Komen also ranked second among the most trusted non-profit organizations in America (behind St. Jude Research Hospital). The rankings examined 1,151 organizations. "We are enormously humbled to be recognized in this way by the public that we serve," said Komen founder and CEO, Ambassador Nancy G. Brinker. "This validation redoubles our resolve to our promise to end breast cancer through science, education, advocacy and relevant support programs all around the world." Harris Interactive Senior Vice President of Public Affairs, Justin Greeves, said of the top-performing non-profits: "They are working to solve many of society's most complex and relevant problems in efficient, new, and innovative ways and have achieved personal relevance in many of our lives - that is why they are at the top." Brinker founded Komen in 1982 after promising her sister, Susan G. Komen, that she would do everything she could to end breast cancer. Susan G. Komen died of breast cancer in 1980 at the age of 36, after a three-year battle with the disease. Since then, through its signature Susan G. Komen Race for the Cure(R) series and corporate business partnerships, Komen has built a grassroots organization supported by and serving millions of women and men on five continents. Komen's nearly $1.5 billion investment in research and community program funding to date has led to five year survival rates of 98 percent for breast cancers that haven't spread from the breast, along with breakthrough treatments that are helping people live longer with the disease. Komen makes it a priority through its global network to ensure that women and men are educated about this disease, they have access to treatment, and that they and their families are supported through a diagnosis. Through Komen's 125 global Affiliates, the organization has provided more than $500 million in research and $900 million since inception to education, screening and treatment programs in thousands of communities. In 2009 alone, Komen funded nearly 500,000 breast screenings and reached 4 million women with breast health education messaging, while investing $60 million into breast cancer research worldwide. The organization also partners with governments and advocacy groups in 50 countries to raise breast health awareness and provide treatment and support, particularly in countries where medical resources and knowledge about the disease are scarce. Komen has funded almost $40 million in international research and outreach since inception. "Our work is enormously gratifying, but it is far from over when more than 1.3 million and men will be diagnosed with breast cancer and almost 500,000 will die - just this year," Brinker said. As a Global Goodwill Ambassador to the U.N.'s World Health Organization and recipient of the Presidential Medal of Freedom, Brinker has called on U.S. and global health leaders to make cancer control a global health priority. This year, Komen will invest another $50-$60 million into research, with about $20 million targeted to cancer vaccines and other cancer prevention strategies. Brinker also has launched a campaign to explore more cost-effective screening for women's cancers, and is an outspoken advocate for screening and access to treatment for cancer patients in the United States. "Our ongoing mission is to attack breast cancer on all fronts - in science, prevention, education and advocacy for people with the disease, and to do so on a global scale," Brinker said. "We've made tremendous progress to this point, but there is so much more to do. With the ongoing support of our friends, volunteers, partners and advocates, we will continue to hold ourselves to very high standards so that we can continue to earn the public's trust in our mission to end suffering from this disease, forever." About Susan G. Komen for the Cure(R) Nancy G. Brinker promised her dying sister, Susan G. Komen, she would do everything in her power to end breast cancer forever. In 1982, that promise became Susan G. Komen for the Cure and launched the global breast cancer movement. Today, Komen for the Cure is the world's largest grassroots network of breast cancer survivors and activists fighting to save lives, empower people, ensure quality care for all and energize science to find the cures. Thanks to events like the Komen Race for the Cure(R), we have invested nearly $1.5 billion to fulfill our promise, becoming the largest source of nonprofit funds dedicated to the fight against breast cancer in the world. For more information about Susan G. Komen for the Cure, breast health or breast cancer, visit komen.org or call 1-877 GO KOMEN. SOURCE: Susan G. Komen for the Cure Susan G. Komen for the Cure(R) Emily Callahan, 972-855-1607 ecallahan@komen.org or Susan G. Komen for the Cure(R) Andrea Rader, 972-855-4320 arader@komen.org Copyright Business Wire 2010Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Most Early-Stage Breast Cancer Patients May Not Need Radiation After Mastectomy - Science Daily Posted: 05 Mar 2010 03:53 PM PST ScienceDaily (Mar. 8, 2010) — Breast cancer patients with early stage disease that has spread to only one lymph node may not benefit from radiation after mastectomy, because of the low present-day risk of recurrence following modern surgery and systemic therapy, a finding that could one day change the course of treatment for thousands of women diagnosed each year, according to researchers at The University of Texas M. D. Anderson Cancer. The research, presented in the plenary session of the Society of Surgical Oncology Annual Cancer Symposium, showed that stage I and II patients without spread to axillary lymph nodes or with 1-3 lymph nodes with metastasis who received surgery and adjuvant chemotherapy without radiation to the chestwall post-mastectomy had a low overall risk of locoregional recurrences (LRR). According to Henry Kuerer, M.D., Ph.D., professor and Training Program Director in M. D. Anderson's Department of Surgical Oncology, 90 percent of patients diagnosed with node-positive disease will present with three or fewer nodes. An estimated 47,000 women are diagnosed annually with breast cancer involving 1- 3 lymph nodes. Of those, 30,000 have only one lymph node involvement. "There is currently no question that radiotherapy after mastectomy is effective at decreasing the chances of LRR and is indicated in breast cancer patients with lymph node spread in greater than four nodes and where the risk of LRR is higher than 10 to 15 percent. However, the need for post-mastectomy radiation in early stage breast cancer patients has been a topic of great debate within the cancer community for decades," explained Kuerer, the study's senior author. In the 1990s, two landmark randomized trials demonstrated a survival benefit for early stage breast cancer patients with lymph node metastases who received the therapy post-mastectomy, explained Kuerer. Subsequently, in 2005, a meta-analysis of randomized clinical trials that were conducted in the 1960s to 1980s showed both a survival benefit, and a decreased risk of LRR for women with node positive breast cancer. These study findings shifted clinical practice: the National Comprehensive Cancer Network altered their medical guidelines in 2007 to suggest that stage I and II breast cancer patients with one to three lymph node metastases "strongly consider" radiation post-mastectomy. "We have entered a new era of breast cancer diagnosis and treatment. Modern day advances in all modalities have been dramatic and, collaboratively, have had a significant impact on recurrence and survival. Given these advances, the goal of our study was to assess the present-day LRR risk in women who present with smaller breast tumors and metastases to fewer lymph nodes," said Kuerer. Kuerer and his colleagues studied clinical and pathological factors from 1,022 stage I or II breast cancer patients who received a mastectomy at M. D. Anderson between 1997 and 2002. Of those women, 79 percent had no lymph node involvement, 26 percent had 1-3 positive lymph nodes, with the majority having just one positive node. None received post-mastectomy radiation and/or pre-operative chemotherapy; 77 percent received post-operative chemotherapy and/or hormonal therapy. The median age was 54 years and the median follow up time was 7.5 years. The researchers found that there was no statistical difference in the 10-year risk of LRR in women without lymph node spread versus those with spread to one node -- 2.1 percent to 3.3 percent, respectively. The only independent risk factor for LRR was age; patients age 40 and younger, regardless of node involvement, were at significant increased risk for LRR. "For these younger women, not less, but more treatment may be needed," said Rajna Sharma, M.D., a fellow in M. D. Anderson's Department of Surgical Oncology, who presented the findings. "For the overwhelming majority of early-stage breast cancer patients treated with modern surgery and systemic therapies, LRR rates may be too low to justify routine use of post-mastectomy radiation," said Kuerer. "This research will provoke much discussion among those caring for women with early-stage breast disease. Replicating these findings should be a priority to ensure that patients only receive therapy that is medically necessary." In addition to Kuerer and Sharma, other authors on the all-M.D. Anderson study include: Thomas A. Buchholz, M.D., professor, Department of Radiation Oncology; Funda Meric-Bernstam, M.D., professor, Kelly K. Hunt, M.D., professor, Isabelle Bedrosian, M.D., assistant professor, Gildy V. Babiera, M.D., associate professor, Anthony Lucci, M.D., associate professor, Rosa F. Hwang, M.D., assistant professor, Loren L. Rourke, MD., assistant professor, Elizabeth A. Mittendorf, M.D., assistant professor, all in the Department of Surgical Oncology; Steven J. Kronowitz, M.D., associate professor, Department of Plastic Surgery; 4 Savitri Krishnamurthy, M.D., professor, Department of Pathology; Ana M. Gonzalez-Angulo, M.D., associate professor, Department of Breast Medical Oncology; and Wei Qiao, Department of Biostatistics. Story Source: Adapted from materials provided by University of Texas M. D. Anderson Cancer Center, via EurekAlert!, a service of AAAS. Note: If no author is given, the source is cited instead. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Corning Inc. and Susan G. Komen group join to increase cancer awareness - Star-Gazette Posted: 08 Mar 2010 07:57 AM PST Corning Inc. announced the Corning Lab for the Cure program, a first-of-its-kind corporate sponsorship agreement with Susan G. Komen for the Cure. Susan G. Komen for the Cure is the largest funder of breast cancer research outside of the U.S. government. Since 1983 the organization has invested $400 million toward finding a cure, with more than $230 million invested in research projects from 2006 to 2009.
Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment